Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion and/or TP53 mutations-Reference-Cited by-同舟云学术

Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion and/or TP53 mutations

Published:2021-12-16 Issue:24 Volume:138 Page:2589-2592
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Sivina Mariela¹^ORCID,Kim Ekaterina¹,Wierda William G.¹,Ferrajoli Alessandra¹,Jain Nitin¹,Thompson Philip¹,Kantarjian Hagop¹^ORCID,Keating Michael¹,Burger Jan A.¹^ORCID

Affiliation:

1. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

https://ashpublications.org/blood/article-pdf/138/24/2589/1853444/bloodbld2021012315.pdf

Reference10 articles.

1. Treatment of chronic lymphocytic leukemia;Burger;N Engl J Med.,2020

2. Ibrutinib treatment for first-line and relapsed/refractory chronic lymphocytic leukemia: Final analysis of the pivotal phase Ib/II PCYC-1102 study;Byrd;Clin Cancer Res.,2020

3. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial;Al-Sawaf;Lancet Oncol.,2020

4. Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study;Kater;J Clin Oncol.,2020

5. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study;Burger;Leukemia.,2020

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia;Expert Review of Hematology;2024-08-21

2. Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies;Blood;2024-06-20

3. BTK inhibitors in CLL: second-generation drugs and beyond;Blood Advances;2024-05-14

4. Marginal zone lymphoma with severe rashes: A case report;World Journal of Clinical Cases;2024-01-26

5. Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia;Journal of Hematology & Oncology;2023-07-08